• 12 week treatment with BIT225 in combination with IFN/RBV (in progress); awaiting news, and couldnt be too far away??
• Initiate 12 week study of BIT225 with newly approved DAA; team has been quiet, and no news to date on this. This has been raised more than once and particularily included a Pharma partner...... is this just around the corner??
• Demonstrate benefit for difficult to treat populations such as the HCV Gen 3, HCV/HIV co-‐infected and cirrho,c patent
• Partner BIT225 for combination with other DAAs in development - IMHO this is in the winds, team have been quiet, no news on CR. Options; release latest news, spike in price and present offer to institutional investors only OR provide news of current results and the JV with a Pharma Partner...... Michelle / Peter you told investors 2014 was the year...... time to deliver only 3 months remain......
BIT Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
